The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease

Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease

June 14, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
sciencepics/shutterstock.com

sciencepics/shutterstock.com

Complement can deposit in various tissues, and previous studies have associated complement deposition with an increased risk for all-cause mortality and stroke. Now, new research underscores the relationship between rheumatic disease, the complement system and cardiovascular disease. In particular, inflammatory rheumatic disease status appears to be uniquely associated with mononuclear cell infiltrates in the vascular system, as well as observable C3d deposition.

You Might Also Like
  • Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease
  • Lupus Treatment Advances Lag Behind Other Rheumatic Diseases
  • How to Manage, Treat Anemia of Inflammation in Patients with Rheumatic Disease
Explore This Issue
June 2017
Also By This Author
  • Myositis Autoantibodies as Biomarkers

Kelly J. Shields, PhD, of the Allegheny Health Network in Pittsburgh, and colleagues published the results of their analysis of complement in patients with rheumatic disease and coronary artery disease online March 31 in Plos ONE.1 Their cross-sectional study included 60 patients with systemic lupus erythematosus (SLE) and/or rheumatoid arthritis (RA).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“To our knowledge, this is the first study to evaluate complement protein deposition within the vessels of SLE, RA and non-[inflammatory rheumatic disease] patients with [coronary artery disease],” write the authors in their discussion. “The findings support the unique relation between complement and [inflammatory rheumatic disease], in particular SLE. From these findings, two important questions arise, which include the source and the targets of the complement and the complement activation products.”

The investigators sorted patients into one of three groups: those with inflammatory rheumatic disease but without coronary artery disease, those with coronary artery disease but without inflammatory rheumatic disease, and those with both inflammatory rheumatic disease and coronary artery disease. The median age of patients was 57 years in the group with inflammatory rheumatic disease but without coronary artery disease, 70 years in the group with coronary artery disease but no inflammatory rheumatic disease and 70.5 years in the group with both. The researchers noted that patients with SLE and/or RA who also had coronary artery disease experienced a higher number of myocardial infarctions than those in the group with coronary artery disease but without inflammatory rheumatic disease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients in the group with both diseases also had higher circulating levels of systemic inflammatory biomarkers than patients in the other two groups. Moreover, their circulating C3 was associated with inflammatory rheumatic disease duration. In the case of patients in the group with coronary artery disease but without inflammatory rheumatic disease, circulating C3 levels were positively associated with body mass index and C-reactive protein. The researchers also reported that inflammatory rheumatic disease was significantly related to the presence and size of mononuclear cell infiltrates, such that inflammatory rheumatic disease was strongly associated with the presence of mononuclear cell infiltrates ≥50 in the aortic adventitia. Moreover, the presence of mononuclear cell infiltrates was related to C reactive protein and the presence of ≥50 mononuclear cell infiltrates was associated with hypertension and current smoking.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: Clinical, coronary artery disease, outcome, patient care, plasma complement activation, Research, Rheumatic Disease, rheumatology, TreatmentIssue: June 2017

You Might Also Like:
  • Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease
  • Lupus Treatment Advances Lag Behind Other Rheumatic Diseases
  • How to Manage, Treat Anemia of Inflammation in Patients with Rheumatic Disease
  • Exploring the Complement System in Human Disease

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)